The association between control level and self-reported treatment adherence across different treatment types in Japanese asthma patients

Gon, Yasuhiro; Ohyanagi, Naho; Kobayashi, Akihiro

doi:10.1016/j.resinv.2021.02.003

Cited by 6 publications

(4 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 2–4 Patients with asthmatic exacerbation requiring oral corticosteroids (OCSs) or hospitalization have diminished health-related quality of life and high healthcare costs, which influences socioeconomic activity. 4 , 5 The pathophysiology of asthma is often explained by type 2 and non-type 2 inflammation. Severe asthma is recognized as a heterogeneous syndrome and non-type 2 inflammation, mainly composed of neutrophilic inflammation, is responsible for the refractory phenotype.…”

Section: Introductionmentioning

confidence: 99%

Real-World Effectiveness of Dupilumab for Patients with Severe Asthma: A Retrospective Study

Numata

Araya

Miyagawa

et al. 2022

JAA

View full text Add to dashboard Cite

Background Treatment with dupilumab, an anti-interleukin (IL)-4 receptor α monoclonal antibody that blocks both the IL-4 and IL-13 pathways, has demonstrated efficacy for the treatment of severe asthma (SA) with type 2 inflammation. However, few studies have focused on the efficacy of this biologic for the treatment of SA in a real-world setting. Methods From April 2019 to December 2021, 26 Japanese patients with SA received dupilumab at Jikei University Hospital. We retrospectively evaluated the number of moderate-to-severe exacerbations, pulmonary function, maintenance dose of corticosteroids, biomarkers, and adverse events. Results During a mean follow-up period of 12.6 months, 10 patients received dupilumab as the first biologic, and 16 switched to dupilumab from other biologics. Dupilumab treatment significantly reduced the number of annual exacerbations from 3.4 ± 4.1 to 1.6 ± 2.7 (/person-year, p < 0.01) at the last follow-up regardless of previous biologic use. The Asthma Control Test score significantly improved in all patients by six months after administration but tended to worsen by 24 months in patients with previous biologic use. On the other hand, blood eosinophil counts (BECs) transiently increased and peaked three to six months after administration. The peak timing can be affected by previous biologic use. Adverse events included wheezing immediately after injection, hypereosinophilia, mild conjunctivitis, and relapse of chronic eosinophilic pneumonia in the patient switched from benralizumab. Conclusion Dupilumab treatment was useful for patients with SA in a real-world setting. However, the BEC should be monitored carefully, especially in patients who previously received anti-IL-5/IL-5 receptor antibody.

show abstract

Section: Introductionmentioning

confidence: 99%

Real-World Effectiveness of Dupilumab for Patients with Severe Asthma: A Retrospective Study

Numata

Araya

Miyagawa

et al. 2022

JAA

View full text Add to dashboard Cite

show abstract

“…Japanese asthma management guidelines primarily recommend combined ICS/LABA therapy for patients with mild to severe asthma [ 4 , 9 , 10 ]; however, many patients remain NWC despite high adherence to ICS/LABA [ 11 ]. The results of this quantitative analysis of 454 patients with asthma in Japan with good adherence to ICS/LABA showed that patients with NWC asthma had significantly greater HRQoL impairment, work productivity and activity impairment, and cough burden compared with patients with WC asthma.…”

Section: Discussionmentioning

confidence: 99%

“…For adult patients with mild to severe asthma, the Japanese Society of Allergology (JSA) and the Japan Asthma Society’s asthma management guidelines primarily recommend combined inhaled corticosteroid/long-acting β 2 -agonist (ICS/LABA) therapy to control symptoms [ 9 , 10 ]. However, data from the Japan National Health and Wellness Survey 2018 found that 40.3% of patients with asthma have symptoms that are not well controlled (NWC) despite high adherence to ICS/LABA [ 11 ]. A 2019 US study found that 81% of patients with asthma adherent to ICS/LABA continued to experience symptoms and 50% had inadequate asthma control, suggesting that a large burden of disease remains despite following guideline recommendations [ 6 ].…”

Section: Introductionmentioning

confidence: 99%

Relationship Between Asthma Control Status and Health-Related Quality of Life in Japan: A Cross-Sectional Mixed-Methods Study

Nagase,

Ito,

Ishii

et al. 2023

Adv Ther

View full text Add to dashboard Cite

Introduction There is limited information regarding multidimensional relationships between asthma control and health-related quality of life (HRQoL), work productivity, and asthma symptom burden in Japan. Furthermore, systematic qualitative investigations about asthma burden have not been performed. Methods This cross-sectional, mixed-methods study included Japanese patients (≥ 20 years) with asthma adherent to inhaled corticosteroids/long-acting β 2 -agonists (ICS/LABA). The primary endpoint was impact of asthma on HRQoL, measured using the Asthma Health Questionnaire-33 (AHQ-33). Secondary endpoints were cough burden (Japanese-adapted Leicester Cough Questionnaire [J-LCQ]) and impact of asthma on work/activities (asthma-specific Work Productivity and Activity Impairment Questionnaire [WPAI:Asthma]). Quantitative data were assessed for the overall population and for well-controlled (WC) and not well-controlled (NWC) asthma subgroups. Qualitative verbal interviews further assessed the impact of NWC asthma on patients’ HRQoL; emergent themes were extracted using thematic analyses. Results Of 454 patients, 45.2% ( n = 205) had NWC asthma. Patients with NWC asthma had significantly worse asthma- and cough-related HRQoL across all AHQ-33 and J-LCQ domains and significantly greater work and activity impairment versus patients with WC asthma, across all assessed WPAI:Asthma domains. AHQ-33 total score was highly correlated with J-LCQ total and domain scores ( r = − 0.8132 to r = − 0.7407). Nine themes emerged from qualitative interviews and confirmed that patients with NWC asthma had considerable HRQoL impairment due to asthma symptoms. Conclusions Patients with NWC asthma had higher symptom burden and worse HRQoL than patients with WC asthma, despite ICS/LABA adherence. Cough burden correlated with HRQoL, suggesting cough may be one of the key markers to inform treatment strategy for patients with asthma. Supplementary Information The online version contains supplementary material available at 10.1007/s12325-023-02660-5.

show abstract

“…Interestingly, in this study greater adherence was associated with having anxiety and/or depression, taking sick leave due to a respiratory cause, and no previous ICS/LABA treatment. Studies have shown that treatment adherence tends to be higher among patients with uncontrolled and severe asthma 35 , 36 . The fact that taking sick leave was associated with higher adherence may indicate that patients in this study were perhaps more symptomatic or perceived their asthma as severe.…”

Section: Discussionmentioning

confidence: 99%

Characteristics and treatment patterns of patients with asthma on multiple-inhaler triple therapy in Spain

Barrecheguren

Monteagudo

Miravitlles

et al. 2022

npj Prim. Care Respir. Med.

View full text Add to dashboard Cite

The aim of this observational, retrospective study was to describe characteristics, treatment patterns, and adherence among patients with asthma who initiated multiple-inhaler triple therapy (MITT) in Catalonia, Spain. This study used data of patients initiating MITT in 2016 from the SIDIAP (Information System for Research in Primary Care) database, which covers ~80% of the Catalonian population (5.8 million). Of 1,204 patients initiating MITT, 361 (30.0%) stepped down (discontinued ≥ 1 and continued ≥1 MITT component) and 89 (7.4%) stopped all three components of MITT for a period of 60 days during the following 12 months. In the follow-up period, 196 (16.3%) patients were considered adherent to MITT (>0.8 proportion of days covered [PDC]), with a mean (standard deviation) PDC of 0.52 (0.51) days. Given the low adherence and substantial rates of step down/discontinuation among patients initiating MITT, there is an urgent need to implement strategies to improve treatment adherence/persistence.

show abstract

The association between control level and self-reported treatment adherence across different treatment types in Japanese asthma patients

Cited by 6 publications

References 20 publications

Real-World Effectiveness of Dupilumab for Patients with Severe Asthma: A Retrospective Study

Real-World Effectiveness of Dupilumab for Patients with Severe Asthma: A Retrospective Study

Relationship Between Asthma Control Status and Health-Related Quality of Life in Japan: A Cross-Sectional Mixed-Methods Study

Characteristics and treatment patterns of patients with asthma on multiple-inhaler triple therapy in Spain

Contact Info

Product

Resources

About